Should I buy or sell Heron Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HRTX shares. View HRTX analyst ratings or view top-rated stocks .

What is Heron Therapeutics' stock price target for 2024?

2 Wall Street analysts have issued 1 year target prices for Heron Therapeutics' shares. Their HRTX share price targets range from $5.00 to $5.00. On average, they expect the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 81.2% from the stock's current price. View analysts price targets for HRTX or view top-rated stocks among Wall Street analysts .

How have HRTX shares performed in 2024?

Heron Therapeutics' stock was trading at $1.70 at the beginning of 2024. Since then, HRTX shares have increased by 62.4% and is now trading at $2.76. View the best growth stocks for 2024 here .

When is Heron Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our HRTX earnings forecast .

How were Heron Therapeutics' earnings last quarter?

Heron Therapeutics, Inc. (NASDAQ:HRTX) announced its quarterly earnings data on Tuesday, March, 12th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.08. The biotechnology company earned $34.23 million during the quarter, compared to analyst estimates of $30.98 million.

What ETF holds Heron Therapeutics' stock?

Jacob Forward ETF holds 50,351 shares of HRTX stock, representing 4.29% of its portfolio.

What guidance has Heron Therapeutics issued on next quarter's earnings?

Heron Therapeutics updated its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $138.0 million-$158.0 million, compared to the consensus revenue estimate of $139.1 million.

What other stocks do shareholders of Heron Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include Micron Technology (MU) , Pfizer (PFE) , Gilead Sciences (GILD) , Sorrento Therapeutics (SRNE) , NVIDIA (NVDA) , Editas Medicine (EDIT) , Immunomedics (IMMU) , bluebird bio (BLUE) , AT&T (T) and Amarin (AMRN) .

Who are Heron Therapeutics' major shareholders?

Heron Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Congress Park Capital LLC (1.09%), Los Angeles Capital Management LLC (0.33%) and Diversified Trust Co (0.02%). Insiders that own company stock include Adam Morgan, Craig A Collard, Ira Duarte, Kimberly Manhard , Waage Christian and William P Forbes. View institutional ownership trends .

How do I buy shares of Heron Therapeutics?

Shares of HRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Heron Therapeutics have any subsidiaries?

The following companies are subsidiares of Heron Therapeutics: Heron Therapeutics B.V.. Read More

NASDAQ:HRTX

Heron Therapeutics (HRTX) Stock Price, News & Analysis

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

Free HRTX Stock Alerts

$2.85

+0.08 (+2.89%)

(As of 10:21 AM ET)

Compare

Today's Range: $2.70
▼
$2.88
50-Day Range: $2.35
▼
$3.06
52-Week Range: $0.50
▼
$3.22

Volume: 427,304 shs
Average Volume: 2.75 million shs
Market Capitalization: $428.44 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

Get Heron Therapeutics alerts:

Heron Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 81.2% Upside
$5.00 Price Target
Short Interest: Bearish
17.00% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.96
Upright™ Environmental Score
News Sentiment: 0.28
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.22) to ($0.09) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.49 out of 5 stars

Medical Sector

267th out of 914 stocks

Pharmaceutical Preparations Industry

109th out of 424 stocks

3.5

Analyst's Opinion

Consensus Rating
Heron Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Heron Therapeutics has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
17.00% of the outstanding shares of Heron Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Heron Therapeutics has a short interest ratio ("days to cover") of 8.8.
Change versus previous month
Short interest in Heron Therapeutics has recently increased by 0.47%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Heron Therapeutics does not currently pay a dividend.
Dividend Growth
Heron Therapeutics does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Heron Therapeutics has received a 61.27% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Antiemetics and antinauseants (A04)", "Bupivacaine", and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Heron Therapeutics is -1.96.

1.8

News and Social Media Coverage

News Sentiment
Heron Therapeutics has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Heron Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 11 people have searched for HRTX on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.
MarketBeat Follows
Only 9 people have added Heron Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Heron Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.40% of the stock of Heron Therapeutics is held by insiders.
Percentage Held by Institutions
80.01% of the stock of Heron Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Heron Therapeutics are expected to grow in the coming year, from ($0.22) to ($0.09) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Heron Therapeutics is -3.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Heron Therapeutics is -3.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

About Heron Therapeutics Stock (NASDAQ:HRTX)

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

HRTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HRTX Stock News Headlines

April 16, 2024 | seekingalpha.com

Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain

April 13, 2024 | americanbankingnews.com

Needham & Company LLC Reiterates "Buy" Rating for Heron Therapeutics (NASDAQ:HRTX)

April 18, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 12, 2024 | nasdaq.com

Commit To Buy Heron Therapeutics At $2, Earn 22.4% Annualized Using Options

April 11, 2024 | prnewswire.com

Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City

April 10, 2024 | americanbankingnews.com

Heron Therapeutics (NASDAQ:HRTX) Share Price Crosses Above 200-Day Moving Average of $1.82

March 28, 2024 | prnewswire.com

Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference

March 16, 2024 | ca.finance.yahoo.com

HRTX Apr 2024 1.500 call

April 18, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

March 14, 2024 | finance.yahoo.com

Heron Therapeutics Full Year 2023 Earnings: Beats Expectations

March 14, 2024 | marketwatch.com

Heron Therapeutics Soars After 4Q Earnings Beat

March 13, 2024 | theglobeandmail.com

Biotech Finds Mid-Week Success Following Q4 Earnings Release

March 13, 2024 | markets.businessinsider.com

Why Is Postoperative Pain Focused Heron Therapeutics Stock Trading Higher On Wednesday?

March 13, 2024 | finance.yahoo.com

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2023 Earnings Call Transcript

March 13, 2024 | finance.yahoo.com

Q4 2023 Heron Therapeutics Inc Earnings Call

March 12, 2024 | finance.yahoo.com

Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates

March 12, 2024 | finance.yahoo.com

Heron Therapeutics Inc (HRTX) Exceeds Full-Year Revenue Guidance for 2023

March 11, 2024 | msn.com

Heron Therapeutics Q4 2023 Earnings Preview

March 11, 2024 | markets.businessinsider.com

What Wall Street expects from Heron Therapeutics's earnings

March 11, 2024 | benzinga.com

Preview: Heron Therapeutics's Earnings

February 28, 2024 | finance.yahoo.com

Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024

February 28, 2024 | prnewswire.com

Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024

February 24, 2024 | msn.com

Heron Therapeutics (HRTX) Price Target Increased by 18.52% to 6.80

February 22, 2024 | benzinga.com

Heron Therapeutics Stock (NASDAQ:HRTX), Short Interest Report

February 17, 2024 | finance.yahoo.com

HRTX Mar 2024 0.500 call

February 16, 2024 | finance.yahoo.com

Investors in Heron Therapeutics (NASDAQ:HRTX) from five years ago are still down 90%, even after 23% gain this past week

February 12, 2024 | finance.yahoo.com

Ocular Therapeutix (OCUL) Surges 12.9%: Is This an Indication of Further Gains?

See More Headlines

Receive HRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/12/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:HRTX
CUSIP: N/A
CIK: 818033
Web: www.herontx.com
Phone: (858) 251-4400
Fax: 650-365-6490
Employees: 126
Year Founded: 1983

Price Target and Rating

Average Stock Price Target: $5.00
High Stock Price Target: $5.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +80.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.86)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-110,560,000.00
Net Margins: -87.02%
Pretax Margin: -87.02%
Return on Equity: N/A
Return on Assets: -50.61%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.37
Quick Ratio: 1.84

Sales & Book Value

Annual Sales: $127.04 million
Price / Sales: 3.28
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.23) per share
Price / Book: -12.04

Miscellaneous

Outstanding Shares: 150,330,000
Free Float: 140,708,000
Market Cap: $416.41 million
Optionable: Optionable
Beta: 1.68

Social Links

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Craig Alexander Collard (Age 58)
CEO & Director
Ms. Ira Duarte (Age 54)
Executive VP & CFO

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

HRTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Heron Therapeutics stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HRTX shares.
View HRTX analyst ratings or view top-rated stocks.
What is Heron Therapeutics' stock price target for 2024?: 2 Wall Street analysts have issued 1 year target prices for Heron Therapeutics' shares. Their HRTX share price targets range from $5.00 to $5.00. On average, they expect the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 81.2% from the stock's current price.
View analysts price targets for HRTX or view top-rated stocks among Wall Street analysts.
How have HRTX shares performed in 2024?: Heron Therapeutics' stock was trading at $1.70 at the beginning of 2024. Since then, HRTX shares have increased by 62.4% and is now trading at $2.76.
View the best growth stocks for 2024 here.
When is Heron Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our HRTX earnings forecast.
How were Heron Therapeutics' earnings last quarter?: Heron Therapeutics, Inc. (NASDAQ:HRTX) announced its quarterly earnings data on Tuesday, March, 12th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.08. The biotechnology company earned $34.23 million during the quarter, compared to analyst estimates of $30.98 million.
What ETF holds Heron Therapeutics' stock?: Jacob Forward ETF holds 50,351 shares of HRTX stock, representing 4.29% of its portfolio.

What guidance has Heron Therapeutics issued on next quarter's earnings?: Heron Therapeutics updated its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $138.0 million-$158.0 million, compared to the consensus revenue estimate of $139.1 million.
What other stocks do shareholders of Heron Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Editas Medicine (EDIT), Immunomedics (IMMU), bluebird bio (BLUE), AT&T (T) and Amarin (AMRN).
Who are Heron Therapeutics' major shareholders?: Heron Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Congress Park Capital LLC (1.09%), Los Angeles Capital Management LLC (0.33%) and Diversified Trust Co (0.02%). Insiders that own company stock include Adam Morgan, Craig A Collard, Ira Duarte, Kimberly Manhard, Waage Christian and William P Forbes.
View institutional ownership trends.
How do I buy shares of Heron Therapeutics?: Shares of HRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Heron Therapeutics have any subsidiaries?: The following companies are subsidiares of Heron Therapeutics: Heron Therapeutics B.V..
Read More

This page (NASDAQ:HRTX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Heron Therapeutics (HRTX) Stock Price, News & Analysis

Heron Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Heron Therapeutics Stock (NASDAQ:HRTX)

HRTX Stock Price History

HRTX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

HRTX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™